Bank of New York Mellon Corp lifted its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 32.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,027 shares of the biotechnology company's stock after buying an additional 20,638 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.18% of Capricor Therapeutics worth $1,160,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Black Diamond Financial LLC purchased a new position in Capricor Therapeutics during the 4th quarter valued at approximately $3,833,000. New York State Common Retirement Fund boosted its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 5,000 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company's stock valued at $636,000 after purchasing an additional 14,169 shares in the last quarter. SG Americas Securities LLC increased its position in Capricor Therapeutics by 74.8% in the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock worth $211,000 after purchasing an additional 6,552 shares during the last quarter. Finally, Magnus Financial Group LLC purchased a new stake in Capricor Therapeutics during the fourth quarter valued at $276,000. Institutional investors own 21.68% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $34.50.
Check Out Our Latest Stock Analysis on Capricor Therapeutics
Capricor Therapeutics Stock Down 2.6 %
NASDAQ:CAPR traded down $0.31 during mid-day trading on Friday, hitting $11.50. 1,192,327 shares of the stock traded hands, compared to its average volume of 1,403,007. The stock has a market capitalization of $522.91 million, a price-to-earnings ratio of -10.85 and a beta of 4.10. Capricor Therapeutics Inc has a 52 week low of $3.52 and a 52 week high of $23.40. The firm's 50 day moving average is $14.05 and its two-hundred day moving average is $14.79.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. As a group, research analysts predict that Capricor Therapeutics Inc will post -1.21 EPS for the current year.
About Capricor Therapeutics
(
Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
